TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05980806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pacritinib
Description: Participants will receive pacritinib 200 mg twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Participants will receive momelotinib 200 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Participants will receive momelotinib 200 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Participants will receive momelotinib 200 mg once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Momelotinib
Description: Participants will receive momelotinib 200 mg once daily.
Study: NCT06415890

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4-7-8 Breathing Technique
Description: The 4-7-8 breathing technique to be applied to the patients in the experimental group; the patient will be asked to sit or lie in a comfortable position with his/her hands on his/her lap, press the tip of his/her tongue on the tissue protrusion behind the upper front teeth and hold it there during the breathing cycle, breathe in through the nose for four counts, hold the breath for seven counts and then slowly exhale through the mouth for eight counts and complete a set. Within one set of practice, this cycle repeats four times.
Study: NCT05668234

Intervention type: OTHER
Intervention: interview
Description: semi-directive interview
Study: NCT04684719

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: low titer whole blood
Description: low titer whole blood, group O kept to either 21 days or 35 days based upon which preservation process is employed at each respective participating site

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: crystalloid infusion or blood component transfusion resuscitation
Study: NCT06026046

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted sport program based on fencing
Description: This adapted sport program includes 3 to 5 sessions per week of adapted fencing (excluding weekends and public holidays), carried out either by a fencing master trained in adapted sport, or by an APA teacher trained in adapted fencing by the fencing master.~Sessions can last from 10 to 30 minutes. The course of the session is validated by the fencing master and adapted to each patient. The limiting factors are taken into account, in order to direct towards a specific practice.~The sessions are progressive with very short and varied sequences calling on the imagination and experience of the fencing masters.
Study: NCT05441241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leap Motion Controller
Description: The Leap Motion Controller is an infrared device that digitalizes in real-time the movements of the hand above it. This signal will be converted into Musical Instrument Digital Interface (MIDI) and then translated into a sound of a pitch that depends on the distance between the hand and the device. The software is set to produce a pentatonic scale, so every melody created by the patient will sound consonant, and the timbre will be warm, calm and in human vocal range (similar to a cello). The operator will do an example, playing a melody, and will invite the patient to imitate him. When the patient gains confidence with the device, after a limited time lapse (from 30 seconds to 3 minutes), while they are playing it with one hand, the venipuncture is done on the other arm

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional distraction techniques
Description: Common distraction techniques will be used (i.e., visual stimulation, lecture)
Study: NCT05451914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: My Diabetes Care
Description: My Diabetes Care (MDC) is a multi-faceted patient portal intervention for mobile devices that is designed to help patients better understand their diabetes health data as well as promote and support self-management. MDC uses infographics to facilitate patients' understanding of their diabetes health data (e.g., HbA1c, LDL) and provides literacy level-appropriate and tailored diabetes self-care information.
Study: NCT01645293

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetically modified T cells # 1138
Study: NCT05665439

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: radiation for patients with newly diagnosed bone metastases or patients with bone metastases after vertebroplasty
Study: NCT05261386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-008
Description: Treat MGD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBT-008
Description: Treat MGD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CBT-008
Description: Treat MGD
Study: NCT06347198

Intervention type: DRUG
Group type: OTHER
Intervention: Fruquintinib
Description: Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib: 4 mg/d, qd po, administered continuously for 2 weeks, discontinued for 1 week;

Intervention type: DRUG
Group type: OTHER
Intervention: Sintilimab
Description: Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab: 200 mg, i.v.gtt.D1, administered every 3 weeks;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin
Description: Inulin: 5g/d, qd po in the first week, 10g/d, bid po from the second week onwards.
Study: NCT06571305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTI)
Description: BBTI is brief patient-focused intervention for patient-sleep-partner caregiver dyads, aimed at altering participants' sleep behaviors to improve sleep. BBTI utilizes behavioral education in sleep restriction and stimulus control. For sleep restriction, participants will be instructed to limit the time spent in bed, which serves to increase sleep efficiency. For stimulus control, participants will be instructed to go to bed only when feeling sleepy and reserve the bed for sleep and intimacy.~BBTI will be delivered over four weeks, in weekly one-hour sessions, one session per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Sleep Our Sleep (MSOS)
Description: MSOS is a sleep intervention developed by the investigator aimed at improving sleep health for patient-sleep-partner caregiver dyads using behavioral education in sleep behaviors, sleep cognition and sleep in relationship.~MSOS will be delivered over four weeks, in weekly one-hour sessions, one session per week.
Study: NCT05919407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Participants will receive pyridostigmine 10 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amifampridine (base) with modified release
Description: Participants will receive amifampridine (base) with modified release 15 mg or 30 mg tablets.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be identical apart from the active substance (pyridostigmine)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo tablets will be identical apart from the active substance (amifampridine base)
Study: NCT05618522

Intervention type: PROCEDURE
Group type: OTHER
Intervention: vacuum-dehydrated amnion membrane (omnigen)
Description: applying the lens loaded with Omnigen on the cornea

Intervention type: DEVICE
Group type: OTHER
Intervention: the lens loaded with Omnigen
Description: the lens loaded with Omnigen
Study: NCT05647681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Douloff
Description: topic gel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: tablets
Study: NCT05603117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Interpersonal Strategy Building with Audio Reflection (CISBAR)
Description: CISBAR incorporates collaborative, individualized goal-setting, metacognitive strategy training, audio feedback, reflection, and practice, integrated with the Conversational Rating System for ABI (CoRS-ABI) and adding a new method for selecting individualized and equivalently challenging conversation practice topics.
Study: NCT06495372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimenta group (standard of care + Methoxyflurane).
Description: standard of care + Methoxyflurane

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: control group (standard of care + placebo).
Description: standard of care + placebo
Study: NCT05803655

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 36-hour duration between ovulation triggering and oocyte pick-up procedure
Description: 36-hour duration between ovulation triggering and oocyte pick-up procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 38-hour duration between ovulation triggering and oocyte pick-up procedure
Description: 38-hour duration between ovulation triggering and oocyte pick-up procedure
Study: NCT06060236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Description: Ibuprofen 800 Mg İv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: Dexketoprofen 50 Mg İV
Study: NCT04980534

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid and Asbrip
Description: Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Viusid and Asbrip
Description: Patients will be assigned to receive daily oral doses of 4.5gr of Viusid and 10 ml of Asbrip every 8 hours and standard care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 Standard Therapy
Description: Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COVID-19 Standard Therapy
Description: Patients will be assigned to receive the standard therapy for COVID-19 disease: Antibiotic, Antivirals, Analgaesic, Anti-inflammatory drugs.
Study: NCT04923477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise for Rotator Cuff Tendinopathy / Subacromial Pain Syndrome
Description: Therapeutic exercise of resistance and mobility via a combination of HEP and in-person/virtual visits 5 days/ wk. Exercise program instruction in person, then 2-3 visits /wk x 8 wks (in-person or virtual) with a trained professional for the progression of exercises. Adherence to exercise will be measured daily via text and recorded in a mobile app. Patients will start with Phase 1 exercises of shoulder external \& internal rotation, scapular stabilization, and active shoulder elevation; resistance levels of elastic bands will be assigned and progressed based on patient-reported shoulder pain and perceived difficulty. Patients will be advanced to Phase 2 when they complete Phase 1. The exercise protocol will be delivered with the methods previously published by Tate, 2010 and Mintken 2016.
Study: NCT04689659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: chimeric antigen receptor T cell treatment
Description: CD7 CAR T cells will be given once intravenously at one dose (1×106, with an allowance of ± 20%) in patients received previous HSCT donor-derived CAR T cells. Patients who received fresh donor derived CD7 CAR T cells were given initial dose of 1×106, with an allowance of ± 20%. The dose levels may be adjusted during the study based on the specific number of cells on the day of fresh CAR T cells infusion, due to at this time all the patients have completed lymphodepleting, so we adopt the allowance of ±20% for each group of absolute infusion cells. And patients who were lower than the designed dose group were also given infusion, but they will be either assigned to the lower dose group or exclude from safety analysis of designed dose group.
Study: NCT05759975

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy (intraoral)
Description: Intraoral photobiomodulation therapy (660nm, 100mW, 10 J/cm 2 , 3 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation therapy (extraoral)
Description: Extraoral photobiomodulation therapy (810 + 980 nm, 1 W, 6.11 J/cm2 , 30 s/point) for the management of oral side effects related during hematopoietic stem cell transplantation (HSCT). Mainly in the decrease of oral OM rates and OM severity, healing of OM ulcers and pain relief. Second, evaluate quality of life,hyposalivation/xerostomia, functional evaluation and dysfagia, in the arm. All results obtained in the group will be compared with the other arm.
Study: NCT05939531

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BOUNCE Program
Description: Intervention arm: Bone-building exercises will be incorporated into the standard post-stroke exercises, as well as Nutritional intervention consisting of individualized diet plan based on calorie requirement, high-quality protein intake, vitamin D, Calcium and micronutrients with a one-to-one virtual session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard post-stroke care
Study: NCT05990387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Dose-response effect on thermogenesis
Study: NCT05601687

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct Endoscopic Necrosectomy
Description: Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS).After placement of the LAMS, EN shall be performed during the same procedure (Direct EN). After DEN, a 7-Fr/4cm double pigtail and a 7-Fr nasocystic irrigation catheter shall be placed through the LAMS. Endoscopic necrosectomy and VARD shall be repeated as often as clinically indicated and logistically possible with a minimum of one day between procedures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Step-up Approach
Description: Endosonography-guided, transmural drainage of the WONs shall be performed using a lumen-apposing metal stent (LAMS). After placement of the LAMS, a 7-Fr/4cm double pigtail stent and a 7-Fr nasocystic catheter shall be placed through the LAMS.~The effect of the index drainage procedure shall be evaluated every 72 hours and next treatment step will depend on whether the patient's condition improves.~If clinical improvement is observed, the drainage regime continues, and no further therapeutic action shall be taken.~In absence of clinical improvement after 72 hours and if supplementary drainage is impossible, the patient shall proceed to endoscopic necrosectomy (EN) or video-assisted retroperitoneal debridement (VARD). Absence of clinical improvement due to causes not related to the WON treatment, e.g., urinary tract or pulmonary infection or iv catheter sepsis, shall not influence the treatment algorithm of the WON.
Study: NCT05734898

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NKG2D CAR-NK
Description: Lymphodepleting chemotherapy followed by NKG2D CAR-NK infusion
Study: NCT05990387

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control condition
Study: NCT04565626

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional weekend physiotherapy
Description: Patients randomized to intervention would receive a Medical Exercise Bike Pedal Exerciser Mini Peddler to allow for an additional 20 minutes a day of unsupervised physiotherapy both during the week and on weekends.
Study: NCT05981625

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Giomer varnish containing surface pre-reacted glass fillers
Description: Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Giomer varnish containing surface pre-reacted glass fillers
Description: Giomer varnish (PRG barrier coat) will used as the intervention agent in this study. , Giomer is considered as a hybrid material between the resins modified glass ionomers and the composite resins. It is composed of 45% Sio2, 24.5% Na2O, 24.5% Ca O and 6% P2O5~. The presence of sodium is very important due to its bioactivity while the phosphate is responsible for the degree of degradation and formation of apatite. Based on this composition, giomer has several clinical applications in implant, periodontics, bone generation, pulp capping, Root canal treatment, as restorative materials, in air abrasion, enamel remineralization and finally dentin hypersensitivity
Study: NCT05728320

Intervention type: DEVICE
Intervention: Glucose monitoring with flash glucose monitor
Description: All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.

Intervention type: DEVICE
Intervention: Glucose monitoring with flash glucose monitor
Description: All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.

Intervention type: DEVICE
Intervention: Glucose monitoring with flash glucose monitor
Description: All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.

Intervention type: DEVICE
Intervention: Glucose monitoring with flash glucose monitor
Description: All groups will be monitorized with a flash glucose monitor and compared after 7-14 days.
Study: NCT06291948

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira® (adalimumab) AC Pen [Reference Product]
Description: A single subcutaneous dose

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab Richmond [Test Product]
Description: A single subcutaneous dose
Study: NCT04556721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: On the day of surgery, after the establishment of general anesthesia, patients will be paralyzed via rocuronium. At the cessation of the case, an appropriate dose of Sugammadex will be utilized to reverse the rocuronium neuromuscular blockade.
Study: NCT05890248

Intervention type: PROCEDURE
Intervention: Technique
Description: Paravertebral block versus Erector spinea block versus quadratus lamborum block

Intervention type: PROCEDURE
Intervention: Technique
Description: Paravertebral block versus Erector spinea block versus quadratus lamborum block

Intervention type: PROCEDURE
Intervention: Technique
Description: Paravertebral block versus Erector spinea block versus quadratus lamborum block
Study: NCT06446921

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ginger formula
Description: supplement delivering a minimum of 20 mg of gingeroids / d

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: arabic gum
Study: NCT05049590

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Acute normovolemic hemodilution (ANH)
Description: A blood conservation technique that removes whole blood (\~8-10cc/kg) from a patient in the operating room prior to incision.
Study: NCT05235126

Intervention type: DEVICE
Group type: OTHER
Intervention: Decoria intense
Description: All subjects will receive treatment at Visit 1 with the option to receive a touch-up treatment at Visit 2. Evaluation of the nasolabial folds will be performed by PI using the Wrinkle Severity Rating Scale (WSRS).
Study: NCT05945420

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin Acetate
Description: This arm will receive tamsulosin and desmopressin acetate daily a

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This arm will receive tamsulosin and placebo
Study: NCT05771103

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermal Radiofrequency neurolysis of Stellate ganglion
Description: Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: thermal Radiofrequency neurolysis of Stellate ganglion
Description: Stellate ganglion block with alcohol injection versus thermal RF neurolysis of Stellate ganglion
Study: NCT05093439

Intervention type: DIAGNOSTIC_TEST
Intervention: Heart Rate Variability
Description: Heart rate variability wil be calculated from patients' 10 sec ECG with a dedicated software (Kubios).
Study: NCT06482346

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MT-3534
Description: Solution for infusion; Intravenous (IV)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study: NCT05942365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: Drug Warfarin oral Drug midazolam oral
Study: NCT04970277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: drinking water group
Description: Those randomized to drink water group were asked to drink 200 mL colorless water every 10 minutes, starting at the time of capsule ingestion until three times in total.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Those randomized to control group were asked not to drink extra water after capsule ingestion.
Study: NCT06444230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy with Neurodevelopmental technique
Description: participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy with Neurodevelopmental technique
Description: participants will recieve a session of 40 minutes including routine physical therapy along with the neurodevelopmental technique for 3 times a week for 12 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine Physical therapy
Description: participants will recieve a session of 40 minutes including, stretching, neck and trunk stabilization and strengthening exercise followed by a warm up and cool down for 3 times a week for 12 weeks follo